Contact information
Type
Scientific
Primary contact
Prof Anthony David
ORCID ID
Contact details
Institute of Psychiatry
P.O. Box 68
De Crespigny Park
Denmark Hill
London
SE5 8AF
United Kingdom
+44 (0)207 848 0138
A.David@iop.kcl.ac.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
KCL/KCH-CT2004-1
Study information
Scientific title
Acronym
EQuiPP
Study hypothesis
The study hypothesis is that Quetiapine is effective in the treatment of the psychotic symptoms (hallucinations/delusions) seen in Parkinson's disease
Ethics approval
Not provided at time of registration
Study design
Randomised placebo controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Not specified
Trial type
Treatment
Patient information sheet
Condition
Parkinson's disease
Intervention
Quetiapine versus Placebo
Intervention type
Drug
Phase
Not Specified
Drug names
Quetiapine
Primary outcome measure
1. Improvment in psychotic symptoms
2. Parkinsonian symptoms
3. Depressive symptoms
4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen)
Secondary outcome measures
1. Activities of daily living
2. Cognitive function
3. Carer burden
Overall trial start date
01/08/2005
Overall trial end date
01/08/2006
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
60
Participant exclusion criteria
1. Anti-psychotic medication in the preceding 3 months
2. Any contra-indication to quetiapine
3. Any important drug interactions
4. Major concomitant medical illness
5. History of uncontrolled diabetes or hypertension
6. Changes in medication in the last 14 days
Recruitment start date
01/08/2005
Recruitment end date
01/08/2006
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Institute of Psychiatry
London
SE5 8AF
United Kingdom
Sponsor information
Organisation
King's College London (UK)
Sponsor details
c/o Gill Dale
P.O. Box 005
The Institute of Psychiatry
De Crespigny Park
Denmark Hill
London
SE5 8AF
United Kingdom
Sponsor type
University/education
Website
Funders
Funder type
Charity
Funder name
Parkinson's Disease Society (UK) (Ref: 4052)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19557142
Publication citations
-
Results
Shotbolt P, Samuel M, Fox C, David AS, A randomized controlled trial of quetiapine for psychosis in Parkinson's disease., Neuropsychiatr Dis Treat, 2009, 5, 327-332.